Company Monitoring Page for Biomarin

latest headlines for company on cafepharma

With ‘breakthrough’ status and a handy nickname, BioMarin plots speedy PhIII for gene therapy
Endpoints
Sun, 10/29/17 - 10:04 am
Tags:
Biomarin, gene therapy, BMN 270, hemophilia A
BioMarin says the FDA game clock now ticking on their blockbuster hopeful pegvaliase
Endpoints
Wed, 08/30/17 - 10:01 am
Tags:
Biomarin, FDA, pegvaliase, PDUFA
Biomarin announces new investments in Ireland
GoInPharma
Sat, 08/12/17 - 11:47 am
Tags:
Biomarin, Ireland
BioMarin may have lost the battle in DMD rivalry, but it won a $35M argument with Sarepta
Endpoints
Tue, 07/18/17 - 09:28 am
Tags:
Biomarin, Sarepta Therapeutics, Duchenne Muscular Dystrophy, Exondys 51
BioMarin, Spark, raising the stakes for hemophilia
BioPharma Dive
Wed, 07/12/17 - 02:48 pm
Tags:
Biomarin, Spark Therapeutics, hemophilia, BMN 270, SPK-9001, gene therapy
BioMarin CEO says 'the system will have to determine' the worth of its new $702,000 drug
CNBC
Sun, 04/30/17 - 12:51 pm
Tags:
Biomarin, Brineura, drug pricing, Batten disease
4 Drug Stocks With Big News Coming in April
Motley Fool
Tue, 04/4/17 - 12:11 am
Tags:
Neurocrine, Incyte, Eli Lilly, Biomarin, Ingrezza, baricitinib, Brineura
BioMarin Pharmaceutical Inc. Logs a Combined Blockbuster
Motley Fool
Sat, 02/25/17 - 03:19 pm
Tags:
Biomarin, earnings, Vimizim, Kuvan, Naglazyme
BioMarin sues to stop generic version of its $90K-a-year drug
Bizjournals.com
Mon, 02/6/17 - 10:04 pm
Tags:
Biomarin, generics, Kuvan, Dr Reddy's
Biotech Investing: 3 Bold Predictions for 2017
Motley Fool
Fri, 01/6/17 - 09:47 am
Tags:
biotech, Incyte, Biogen, Biomarin, Gilead Sciences, Illumina
7 of the Most Shocking Biotech Pipeline Blowups of 2016
Motley Fool
Sun, 12/4/16 - 12:37 pm
Tags:
biotech, Alnylam, revusiran, Clovis Oncology, rociletinib, Celldex Therapeutics, Rintega, Eli Lilly, solanezumab, Novavax, RSV-F, Arrowhead, ARC-520, ARC-521, ARC-AAT, Biomarin, drisapersen
BioMarin’s Disappointing 3Q16 Earnings
Market Realist
Mon, 10/31/16 - 06:34 pm
Tags:
Biomarin, earnings
Sarepta Therapeutics' Greatest Threat: Anthem?
Motley Fool
Mon, 10/17/16 - 11:41 am
Tags:
Sarepta Therapeutics, Duchenne Muscular Dystrophy, Exondys 5, Biomarin, Anthem
FDA’s controversial OK for eteplirsen spurs second thoughts for a rejected rival at BioMarin
Endpoints
Thu, 10/13/16 - 03:33 pm
Tags:
FDA, eteplirsen, Duchenne Muscular Dystrophy, Biomarin, Sarepta Therapeutics
3 Biotechs Most Likely to Be Acquired
Motley Fool
Tue, 10/11/16 - 09:45 pm
Tags:
biotech, M&A, Incyte, Biomarin, Biogen
After Sarepta win, BioMarin appeals DMD patent ruling
BioPharma Dive
Fri, 09/23/16 - 09:35 am
Tags:
Sarepta Therapeutics, Biomarin, patents, Duchenne Muscular Dystrophy, eteplirsen, Kyndrisa
BioMarin hits snag with latest rare disease drug
BioPharma Dive
Wed, 09/7/16 - 08:34 pm
Tags:
Biomarin, Brineura, FDA, CLN2 disease
3 Biotech Stocks Could Be the Next Big Takeover Targets
24/7 Wall St
Wed, 08/31/16 - 09:20 am
Tags:
biotech, M&A, Biomarin, Incyte, Tesaro
4 Biotech Buyout Targets for Gilead, Sanofi After Medivation Miss
Barron's
Tue, 08/23/16 - 11:11 am
Tags:
biotech, M&A, Gilead Sciences, Sanofi, Medivation, Incyte, Biomarin, Tesaro, Seattle Genetics
Sarepta: The Competition Is At The Gate
Seeking Alpha
Fri, 08/12/16 - 09:53 am
Tags:
Sarepta Therapeutics, eteplirsen, Biomarin, Summit Therapeutics, PTC Therapeutics, Duchenne Muscular Dystrophy

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.